Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G (2014) Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 20:9633–9652
Article
PubMed
PubMed Central
Google Scholar
Yamaoka K, Nouchi T, Marumo F, Sato C (1993) Alpha-smooth-muscle actin expression in normal and fibrotic human livers. Dig Dis Sci 38:1473–1479
Article
CAS
PubMed
Google Scholar
Ge PS, Runyon BA (2016) Treatment of patients with cirrhosis. N Engl J Med 375:767–777
Article
CAS
PubMed
Google Scholar
Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH et al (1996) The long-term pathological evolution of chronic hepatitis C. Hepatology 23:1334–1340
Article
CAS
PubMed
Google Scholar
Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231
Article
CAS
PubMed
Google Scholar
Neuman MG, Cohen LB, Nanau RM (2016) Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochem 49:302–315
Article
CAS
PubMed
Google Scholar
Bedossa P, Carrat F (2009) Liver biopsy: the best, not the gold standard. J Hepatol 50:1–3
Article
PubMed
Google Scholar
Papastergiou V, Tsochatzis E, Burroughs AK (2012) Non-invasive assessment of liver fibrosis. Ann Gastroenterol 25:218–231
PubMed
PubMed Central
Google Scholar
Aikawa S, Hashimoto T, Kano K, Aoki J (2015) Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem 157:81–89
Article
CAS
PubMed
Google Scholar
Moolenaar WH, van Meeteren LA, Giepmans BN (2004) The ins and outs of lysophosphatidic acid signaling. Bioessays 26:870–881
Article
CAS
PubMed
Google Scholar
Jansen S, Andries M, Vekemans K, Vanbilloen H, Verbruggen A, Bollen M (2009) Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 284:216–221
Article
CAS
PubMed
Google Scholar
Kaffe E, Katsifa A, Xylourgidis N, Ninou I, Zannikou M, Harokopos V, Foka P, Dimitriadis A et al (2017) Hepatocyte autotaxin expression promotes liver fibrosis and cancer. Hepatology 65:1369–1383
Article
CAS
PubMed
Google Scholar
Pleli T, Martin D, Kronenberger B, Brunner F, Köberle V, Grammatikos G, Farnik H, Martinez Y et al (2014) Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis--a prospective cohort study. PLoS One 9:e103532
Article
PubMed
PubMed Central
Google Scholar
Nakamura K, Ohkawa R, Okubo S, Tozuka M, Okada M, Aoki S, Aoki J, Arai H et al (2007) Measurement of lysophospholipase D/autotaxin activity in human serum samples. Clin Biochem 40:274–277
Article
CAS
PubMed
Google Scholar
Yamazaki T, Joshita S, Umemura T, Usami Y, Sugiura A, Fujimori N, Shibata S, Ichikawa Y et al (2017) Association of serum autotaxin levels with liver fibrosis in patients with chronic hepatitis C. Sci Rep 7:46705
Article
CAS
PubMed
PubMed Central
Google Scholar
Yamazaki T, Joshita S, Umemura T, Usami Y, Sugiura A, Fujimori N, Kimura T, Matsumoto A et al (2018) Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C. PLoS One 13:e0195632
Article
PubMed
PubMed Central
Google Scholar
Joshita S, Ichikawa Y, Umemura T, Usami Y, Sugiura A, Shibata S, Yamazaki T, Fujimori N et al (2018) Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection. Hepatol Res 48:275–285
Article
CAS
PubMed
Google Scholar
Fujimori N, Umemura T, Kimura T, Tanaka N, Sugiura A, Yamazaki T, Joshita S, Komatsu M et al (2018) Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease. World J Gastroenterol 24:1239–1249
Article
CAS
PubMed
PubMed Central
Google Scholar
Joshita S, Umemura T, Usami Y, Yamashita Y, Norman GL, Sugiura A, Yamazaki T, Fujimori N et al (2018) Serum autotaxin is a useful disease progression marker in patients with primary biliary cholangitis. Sci Rep 8:8159
Article
PubMed
PubMed Central
Google Scholar
Wu JM, Xu Y, Skill NJ, Sheng H, Zhao Z, Yu M, Saxena R, Maluccio MA (2010) Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer 9:71
Article
CAS
PubMed
PubMed Central
Google Scholar
Enooku K, Uranbileg B, Ikeda H, Kurano M, Sato M, Kudo H, Maki H, Koike K et al (2016) Higher LPA2 and LPA6 mRNA levels in hepatocellular carcinoma are associated with poorer differentiation, microvascular invasion and earlier recurrence with higher serum autotaxin levels. PLoS One 11:e0161825
Article
PubMed
PubMed Central
Google Scholar
Baader M, Bretschneider T, Broermann A, Rippmann JF, Stierstorfer B, Kuttruff CA, Mark M (2018) Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis. Br J Pharmacol 175:693–707
Article
CAS
PubMed
PubMed Central
Google Scholar
Saleh S, Salama M, Alhusseini M, Mohamed G (2020) M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J Gastroenterol 26:2864–2876
Article
CAS
PubMed
PubMed Central
Google Scholar
Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M et al (2017) The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One 12:e0182710
Article
PubMed
PubMed Central
Google Scholar
Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, Braun D, Seifert B et al (2017) Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int 37:369–376
Article
CAS
PubMed
Google Scholar
Kostadinova L, Shive CL, Judge C, Zebrowski E, Compan A, Rife K, Hirsch A, Falck-Ytter Y et al (2016) During hepatitis C virus (HCV) infection and HCV-HIV coinfection, an elevated plasma level of autotaxin is associated with lysophosphatidic acid and markers of immune activation that normalize during interferon-free HCV therapy. J Infect Dis 214:1438–1448
Article
CAS
PubMed
PubMed Central
Google Scholar
Ando W, Yokomori H, Kaneko F, Kaneko M, Igarashi K, Suzuki H (2018) Serum autotaxin concentrations reflect changes in liver stiffness and fibrosis after antiviral therapy in patients with chronic hepatitis C. Hepatol Commun 2:1111–1122
Article
CAS
PubMed
PubMed Central
Google Scholar
Kostadinova L, Shive CL, Zebrowski E, Fuller B, Rife K, Hirsch A, Compan A, Moreland A et al (2018) Soluble markers of immune activation differentially normalize and selectively associate with improvement in AST, ALT, albumin, and transient elastography during IFN-free HCV therapy. Pathog Immun 3:149–163
Article
PubMed
PubMed Central
Google Scholar
Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK (2011) Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 54:650–659
Article
CAS
PubMed
Google Scholar
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38:518–526
Article
PubMed
Google Scholar
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1325
Article
CAS
PubMed
Google Scholar
van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, Pettit TR, Wakelam MJ et al (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26:5015–5022
Article
PubMed
PubMed Central
Google Scholar
Shao X, Uojima H, Setsu T, Okubo T, Atsukawa M, Furuichi Y, Arase Y, Hidaka H et al (2020) Usefulness of autotaxin for the complications of liver cirrhosis. World J Gastroenterol 26:97–108
Article
CAS
PubMed
PubMed Central
Google Scholar
Ferry G, Tellier E, Try A, Grés S, Naime I, Simon MF, Rodriguez M, Boucher J et al (2003) Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278:18162–18169
Article
CAS
PubMed
Google Scholar
Benesch MG, Ko YM, McMullen TP, Brindley DN (2014) Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions. FEBS Lett 588:2712–2727
Article
CAS
PubMed
Google Scholar